All News
Associations in Rheumatology (10.3.2025)
Dr. Jack Cush reviews the news, journal reports and important associations in rheumatology from the past week on RheumNow.com.
Read Article
Guselkumab FDA Approved for Pediatric Psoriasis and Psoriatic Arthritis
FDA announced yesterday that guselkumab (Tremfya) is approved for use in pediatric patients moderate to severe plaque psoriasis (PsO) or active psoriatic arthritis (PsA) in children six years and older (weighing at least 40 kg).
Read Article
How Does Your Garden Grow (9.26.2025)
Dr. Jack Cush reviews the news and journal articles from RheumNow.com. Pool therapy, Fibrosis, NSIE's and what's best for knee OA.
Read Article
Equal Safety of JAK Inhibitors and TNF Inhibitors
JAMA has published a systematic review and meta-analysis of head-to-head studies showing there was no meaningful difference in safety events observed when taking either JAK inhibitor (JAKi) vs TNF antagonist (TNFi) therapies for the treatment of immune-mediated
RheumNow Podcast – Ro, Ro, Ro52 (9.12.2025)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Are there benefits to diet or vegan diets? What's the effect of menopause on CTD? Ro52 makes a big entrance with all our ILD coverage this month.
Read Article
Small 38 pt. RCT found that 16-wks of Mediterranean diet signif improved psoriasis PASI scores. Intervention grp had better PASI change at week 16 (−3.4 vs 0), PASI 75, and reducted hemoglobin A1c. Diet as adjunctive Rx in PsO!! https://t.co/oJnaAA8LMm https://t.co/AXxI8FWQqU
Dr. John Cush RheumNow ( View Tweet)
Chronic urticaria (CU) may be a presenting feature of an autoinflammatory syndrome (monogenic or multifactorial) - disorders to consider: cryopyrin-associated periodic (CAPS), Schnitzler, Still's disease, & neutrophilic urticarial dermatosis https://t.co/GKYqFzX6A0 https://t.co/QEEaw9zNjH
Dr. John Cush RheumNow ( View Tweet)
QD Clinic: ILD with Positive SSA and Rash
Dr. Elena Joerns, Rochester, Minnesota discusses a case of ILD with positive SSA and rash, as part of RheumNow's Rheum to Breathe: ILD campaign, presented throughout the month of September 2025.
https://t.co/Yuz8CuIN5H https://t.co/3M9emsIXVf
Dr. John Cush RheumNow ( View Tweet)
Turkish study of 799 psoriasis pts - 30% had concurrent onset PsO & PsA & in 70% there was a long transition time (~13 yrs) from PsO-to-PsA. Factors assoc w/ prolonged interval included Depression, fatigue, scalp PsO(OR 7), nail PsO (3.2), +Fhx & enthesitis ever (OR 2) https://t.co/wqtSbeQ2vz
Dr. John Cush RheumNow ( View Tweet)
DERM on RheumNow Podcast (September 2025)
Content curated for dermatologists and skin deep HCPs – on Psoriasis, CLE, vasculitis, HS and dermatology drugs use, efficacy and side effects and more.
https://t.co/zZpheX1epS https://t.co/uOd9Gy0V2E
Dr. John Cush RheumNow ( View Tweet)
Report of 54 Sjögren dz pts w/ cutaneous vasculitis (CV); most had cryoglobulinemic vasculitis & hypergammaglob.vasculitis. Sjogrens w/ CV had higher risk of lymphoma. Type II cryoglob. vasculitis incr risk of mortality/lymphoma, renal dz, peripheral nerve involvement https://t.co/7UPFd2dSZU
Dr. John Cush RheumNow ( View Tweet)
Cross-sectional study of 320 dermatomyositis (198 classic DM, 122 amyopathic DM/CADM) & compared myositis panels for ANA, MSA, MAA, etc. Comparing CDM vs CADM - ANA pos in 63% vs 49%, p<0.05; MSA+ 47% vs 40% (NS); MAA+ 29% vs 26%(NS); MSA&MAA neg 40% vs 48% (NS)
Dr. John Cush RheumNow ( View Tweet)
Global prevalence of Hidradenitis suppurativa (HS) is 0.99%, but varies globally between 0.67% and 1.46%. HS is assoc w/ female sex. Based on a meta-analysis 22 743 participants, identifying 247 HS pts. https://t.co/TtKdfKiIn3 https://t.co/zOIVUlF5E8
Dr. John Cush RheumNow ( View Tweet)
New #therapy in #SLE
#lupus https://t.co/TPeKxfw9hq
Dr hanady manasfi hanadymanasfi ( View Tweet)
What Is Lyme Disease?
JAMA Patient education handout. Lyme disease is the most common tick-borne infection in the US. A bite from infected Ixodes scapularis ticks can transmit the bacterium Borrelia burgdorferi, which causes Lyme disease. https://t.co/a8eMdAy0bi https://t.co/Jrj4Eiuy24
Dr. John Cush RheumNow ( View Tweet)
Metanalysis shows patients w/ psoriasis have signif. higher risk (2-2.5 fold) of metabolic syndrome compared to the general population, RA or spondylitis patients. Comparing PsO to PsA there is no difference (PsA also has a high riskof MetS). https://t.co/gO3IomfP53 https://t.co/Ov2UHV2mN6
Dr. John Cush RheumNow ( View Tweet)
AbbVie announces positive topline results from a 2nd Phase 3 UP-AA Trial evaluating Upadacitinib in Alopecia Areata (AA) - w/ 45% and 55% of severe AA pts rx w/ UPA 15 mg and 30 mg, achieving a SALT score ≤ 201 (80% or more scalp hair coverage) at week 24 https://t.co/8p1FvJx0s0
Dr. John Cush RheumNow ( View Tweet)
ChildCAPTURE & BioCAPTURE registry studies of 117 pediatric & 243 young adult Psoriasis pts on biologics (753.4 Pt-Yrs) shows no sex differences in clinical responses, but shows females have more adverse events than males (both cohorts) https://t.co/5at9vCqwIO https://t.co/ScJkIH9G31
Links:
Dr. John Cush RheumNow ( View Tweet)
Anifrolumab appears effective & safe in refractory Cutaneous LE. OL Study of 15 CLE, on HCQ, topical steroids, failed multiple DMARDs. All Rx w/ ANIF 300 mg IV q4wks. ALL improved, CLASI-A decr from 16 to 1 (p<0.001); CLASI-D decreased from 5 to 4 (p<0.001). DBPCT needed! https://t.co/umEYz0XDyt
Dr. John Cush RheumNow ( View Tweet)
Nailfold videocapillaroscopy (NVC) in Dx of systemic sclerosis - study of 258 NVCs found giant capillaries (specificity 98%) & capillary density to be best at defining a scleroderma pattern (39%). Density ≤8 capillaries/mm best defined dropout (AUC 0.911); having both = 91% https://t.co/zyoe7ofGLR
Dr. John Cush RheumNow ( View Tweet)
